Short Communication: Update in Natural Antiretroviral Resistance-Associated Mutations Among HIV Type 2 Variants and Discrepancies Across HIV Type 2 Resistance Interpretation Tools

Abstract

HIV variants carry natural polymorphisms related to drug resistance (R-markers) fixed during viral evolution in the absence of antiretroviral therapy (ART) that may impact on drug susceptibility and resistance pathways. We aimed to identify the HIV type 2 (HIV-2) variant-specific R-markers at Pol in all available sequences from ART-naive subjects deposited in Los Alamos database according to reported HIV-2 drug resistance-associated mutations (DRMs) and report the performance of two online HIV-2 resistance interpretation tools (HIV2EU Tool and Stanford HIVdb Program for HIV-2) to detect them. From a total of 587 sequences, we found 23 R-markers in low frequency, in groups A, B, and G. Four were present in >10% of the sequences with no direct impact on antiretroviral susceptibility. HIV2EU Tool detected one, whereas Stanford program all four. Stanford new tool, although still under development, seems effective in detecting HIV-2 DRMs and may prove a useful tool for HIV-2 resistance interpretation when fully developed.

Get full access to this article

View all access options for this article.

References

Clavel

, Guétard

, Brun-Vézinet

, et al.: Isolation of a new human retrovirus from West African patients with AIDS. Science, 1986; 233:343–346.

Pereira

JMA

, Costa

: HIV interaction with human host: HIV-2 as a model of a less virulent infection. Aids Rev, 2016; 18:44–53.

Visseaux

, Damond

, Matheron

, Descamps

, Charpentier

: Hiv-2 molecular epidemiology. Infect Genet Evol, 2016; 46:233–240.

Menéndez-Arias

, Álvarez

: Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral Res, 2014; 102:70–86.

Desbois

, Roquebert

, Peytavin

, et al.: In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother, 2008; 52:1545–1548.

Tuaillon

, Gueudin

, Lemee

, et al.: Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr, 2004; 37:1543–1549.

Roquebert

, Damond

, Collin

, et al.: HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother, 2008; 62:914–920.

Charpentier

, Camacho

, Ruelle

, et al.: HIV-2EU—Supporting Standardized HIV-2 drug-resistance interpretation in Europe: An update. Clin Infect Dis, 2015; 61:1346–1347.

Tzou

, Descamps

, Rhee

S-Y

, et al.: Expanded spectrum of antiretroviral-selected mutations in human immunodeficiency virus type 2. J Infect Dis, 2020; 221:1962–1972.

10.

de Mendoza

, Lozano

, Caballero

, Cabezas

, Ramos

, Soriano

: Antiretroviral therapy for HIV-2 infection in non-endemic regions. AIDS Rev, 2020; 22:44–56.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB